Transthyretin Amyloidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Players - Attralus, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Novo Nordisk

The transthyretin amyloidosis market size is projected to grow significantly during the forecast period (2023–2032) owing to the currently approved drugs, along with the launch of upcoming therapies and the increasing prevalence of the disease. With the launch of these therapies, many new players are expected to enter the ATTR market space.

LAS VEGAS, Jan. 24, 2024 /PRNewswire/ -- DelveInsight's Transthyretin Amyloidosis Market Insights report includes a comprehensive understanding of current treatment practices, transthyretin amyloidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Transthyretin Amyloidosis Market Report

• According to DelveInsight's analysis, the market size for ATTR across the 7MM is expected to grow with a significant CAGR by 2032.
• DelveInsight's analysis reveals that the overall diagnosed prevalent population of hATTR in the 7MM was reported as ~15K in 2022. 
• Leading transthyretin amyloidosis companies such as Attralus, Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Inc., AstraZeneca, Alexion Pharmaceuticals, Inc., Novo Nordisk A/S, Eidos Therapeutics, and others are developing novel ATTR drugs that can be available in the ATTR market in the coming years.
• The promising transthyretin amyloidosis therapies in the pipeline include I 124-Evuzamitide, Vutrisiran, Eplontersen, Patisiran, ALXN2220, NNC6019-0001, Acoramidis (AG10), and others.

Discover which therapies are expected to grab the major ATTR market share @ Transthyretin Amyloidosis Market Report

Transthyretin Amyloidosis Overview

Transthyretin Amyloidosis (ATTR) is an rare genetic disorder marked by the accumulation of abnormal amyloid protein deposits, categorized into two primary types: hereditary ATTR (hATTR) and wild-type ATTR (wtATTR). hATTR results from inherited mutations in the TTR gene, while wtATTR affects individuals without identified genetic mutations and is more commonly linked to aging. Managing Transthyretin Amyloidosis poses various challenges, including its frequent underdiagnosis or misdiagnosis due to its rarity and the diverse range of symptoms, leading to a delayed initiation of appropriate treatment. Crafting tailored treatment plans for individual patients is intricate due to the heterogeneity of the disease. Diagnosing ATTR amyloidosis typically involves a blend of clinical assessment, genetic testing to pinpoint TTR mutations, and imaging studies like cardiac MRI or nuclear scintigraphy to evaluate organ involvement and amyloid deposition.

Transthyretin Amyloidosis Epidemiology Segmentation

The ATTR epidemiology section provides insights into the historical and current ATTR patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The ATTR market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Diagnosed Prevalent Population of Transthyretin Amyloidosis
• Type-specific Diagnosed Prevalent Cases of Transthyretin Amyloidosis
• Type-specific Diagnosed Prevalent Population of Hereditary Transthyretin Amyloidosis

Transthyretin Amyloidosis Treatment Market 

Presently, existing treatments aim to reduce the presence of transthyretin (TTR) protein in the body, thereby lessening amyloid deposits and potentially reducing symptoms linked to hATTR. Another strategy involves eliminating the origin of altered TTR, while alternative treatments focus on preventing the abnormal shaping of TTR protein, which leads to deposits in tissues and crucial organs.

The therapeutic choices for individuals with hATTR are limited. While a liver transplant remains the preferred method since the majority of the amyloidogenic TTR protein is generated in the liver, replacing the primary source of this problematic protein with a transplanted liver can nearly eradicate variant protein production and effectively impede the progression of the disease outside the brain and eyes. Despite its efficacy, a liver transplant does not adequately prevent cardiomyopathy in the majority of cases, and it is not advisable for those with advanced-stage transthyretin-related familial amyloid polyneuropathy (TTR-FAP) or leptomeningeal-type amyloidosis. Consequently, for these patients, relief from symptoms stands as the sole available treatment.

In hATTR, mutations are believed to undermine the interactions within the typically tetrameric TTR, leading to its separation into monomeric TTR. This monomeric form is prone to misfolding and aggregation, contributing to the formation of amyloid fibrils. Therefore, a strategy to prevent the dissociation of TTR tetramers is crucial in averting the development of amyloid fibrils. In 2019, the US FDA granted approval for VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) capsules to treat cardiomyopathy resulting from transthyretin-mediated amyloidosis (ATTR-CM) in adults. 

These capsules act as disease-modifying agents by kinetically stabilizing the TTR protein. This stabilization is beneficial as it curtails the dissociation of the native TTR tetramer into monomers, a pivotal step in fibril formation, thereby inhibiting the creation of TTR amyloid fibrils. Moreover, they further enhance the stability of the transthyretin protein, decelerating the process of amyloid deposit formation. In certain regions, these capsules are also available for treating hATTR polyneuropathy. Additionally, research indicates that tafamidis is well-tolerated and may slow down disease progression in patients with stage I, although some gastrointestinal side effects and occurrences of urinary tract and vaginal infections may arise.

To know more about ATTR treatment guidelines, visit @ Transthyretin Amyloidosis Management 

Transthyretin Amyloidosis Pipeline Therapies and Key Companies

• I 124-Evuzamitide: Attralus, Inc.
• Vutrisiran: Alnylam Pharmaceuticals
• Eplontersen: Ionis Pharmaceuticals, Inc./AstraZeneca
• Patisiran: Alnylam Pharmaceuticals
• ALXN2220: Alexion Pharmaceuticals, Inc.
• NNC6019-0001: Novo Nordisk A/S
• Acoramidis (AG10): Eidos Therapeutics

Learn more about the FDA-approved drugs for ATTR @ Drugs for Transthyretin Amyloidosis Treatment 

Transthyretin Amyloidosis Market Dynamics

The dynamics of the transthyretin amyloidosis market are expected to change in the coming years. The ATTR market landscape is witnessing a transformative shift driven by the emergence of novel therapeutic approaches and a deeper understanding of the disease pathology. The ATTR market is propelled by ongoing research and development endeavors to introduce innovative drugs that target the underlying mechanisms of ATTR, aiming not only to alleviate symptoms but also to modify the course of the disease. 

Furthermore, many potential therapies are being investigated for the treatment of ATTR, and it is safe to predict that the treatment space will significantly impact the ATTR market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the ATTR market in the 7MM.

However several factors may impede the growth of the transthyretin amyloidosis market. One primary obstacle is the intricate nature of the disease itself. ATTR encompasses various clinical manifestations, making drug development challenging due to the necessity for tailored approaches for different subtypes. Additionally, diagnostic challenges hinder timely identification, leading to delayed treatment initiation.

Moreover, ATTR treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the ATTR market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the ATTR market growth.

Scope of the Transthyretin Amyloidosis Market Report

• Therapeutic Assessment: Transthyretin Amyloidosis current marketed and emerging therapies
• Transthyretin Amyloidosis Market Dynamics: Key Market Forecast Assumptions of Emerging Transthyretin Amyloidosis Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Transthyretin Amyloidosis Market Access and Reimbursement

Discover more about ATTR drugs in development @ Transthyretin Amyloidosis Clinical Trials

Table of Contents

Related Reports

Hereditary Transthyretin Amyloidosis Pipeline

Hereditary Transthyretin Amyloidosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hATTR companies, including Alnylam Pharmaceuticals, IonisPharmaceuticals, EidosTherapeutics, IntelliaTherapeutics, CorinoTherapeutics, Novo Nordisk, among others.

Hereditary Transthyretin Amyloidosis Epidemiology Forecast

Hereditary Transthyretin Amyloidosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted hATTR epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Transthyretin Amyloid Cardiomyopathy Market

Transthyretin Amyloid Cardiomyopathy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ATTR-CM companies, including EidosTherapeutics, NeuraImmuneTherapeutics, among others.

Transthyretin Amyloid Cardiomyopathy Pipeline

Transthyretin Amyloid Cardiomyopathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ATTR-CM companies, including EidosTherapeutics, NeuraImmuneTherapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+91-9650213330
www.delveinsight.com  

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg